Research programme: tuberculosis therapeutics - Lilly TB Drug Discovery Initiative

Drug Profile

Research programme: tuberculosis therapeutics - Lilly TB Drug Discovery Initiative

Alternative Names: BIKAKEN; CPZEN-45

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Institute of Microbial Chemistry; Microbial Chemistry Research Foundation; Summit plc
  • Developer Eli Lilly
  • Class Nucleosides; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Tuberculosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Tuberculosis in USA (Inhalation)
  • 24 Aug 2017 Infectious Disease Research Institute and Zhejiang Hisun Pharmaceutical agree to co-develop CPZEN 45 for tuberculosis
  • 20 Feb 2015 Summit Corporation is now called Summit Therapeuitcs
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top